NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

March 9, 2024

Study Completion Date

June 1, 2027

Conditions

Invasive Breast CancerMetastatic Breast CancerHR-Positive Breast CancerHER2-negative Breast Cancer

Interventions

DRUG

Pembrolizumab

(iv) fixed dose, administered once per cycle

DRUG

Sacituzumab Govitecan

(iv) fixed dose, administered twice per cycle

Trial Locations (8)

University of Pennsylvania-Abramson Cancer Center, Philadelphia

University of North Carolina at Chapel Hill, Chapel Hill

Emory University/Winship Cancer Institute, Atlanta

University of Chicago Medical Center, Chicago

Dana Farber Cancer Institute, Boston

DFCI @ Foxborough, Foxborough

DFCI @ Milford Regional Hospital, Milford

DF/BWCC in Clinical Affiliation with South Shore Hospital, South Weymouth